Rxgoodusa – FDA Warning Letter, Apr 1, 2026

On April 1, 2026, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to Rxgoodusa for the illegal sale of unapproved and misbranded prescription drugs through its website, www.rxgoodusa.com. This action follows a prior 2025 warning issued to the same operator under a different domain. The current investigation revealed that the company continues to distribute high-risk medications, specifically opioids like Tramadol and benzodiazepines such as Diazepam, into interstate commerce without valid prescriptions or FDA approval. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), these products are considered unapproved new drugs and misbranded because they lack adequate directions for safe use by laypeople and bypass essential regulatory safety oversight. The FDA highlighted the severe public health risks associated with the non-medical use of these substances, including addiction, respiratory depression, and death, particularly when taken without professional medical supervision. Rxgoodusa is directed to immediately cease the sale of all unapproved and misbranded medications to U.S. consumers. The company must provide a written response within 15 working days outlining the specific steps taken to correct these violations and prevent their recurrence. Failure to address these concerns may result in legal action, such as product seizures or injunctions. This letter serves as a critical notice to ensure the company aligns its operations with federal safety and effectiveness standards.